| Toufic Imam, MD | |
|
160 S River Rd Ste 100, Bedford, NH 03110-6927 | |
| (603) 665-5160 | |
| (603) 665-5160 |
| Full Name | Toufic Imam |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 18 Years |
| Location | 160 S River Rd Ste 100, Bedford, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588814297 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD449241 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Catholic Medical Center | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Catholic Medical Center | 6103897129 | 248 |
News Archive
Scientists have analyzed compounds in wastewater to gauge various aspects of public health, including narcotics usage, antibiotic resistance, and, more recently, the spread of SARS-CoV-2, the novel coronavirus that causes COVID-19.
Synovis Life Technologies, Inc., today reported its financial results for the third quarter ended July 31, 2010.
BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).
In a new study, Swedish researchers speculate the effects of the present intervention strategies on the healthcare system as the COVID-19 pandemic affects the nation. Their study titled, "Intervention strategies against COVID-19 and their estimated impact on Swedish healthcare capacity," has not been published yet; however, the findings are available as pre-peer-reviewed study at medRxiv.
› Verified 4 days ago
| Entity Name | Catholic Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235370057 PECOS PAC ID: 6103897129 Enrollment ID: O20090701000405 |
News Archive
Scientists have analyzed compounds in wastewater to gauge various aspects of public health, including narcotics usage, antibiotic resistance, and, more recently, the spread of SARS-CoV-2, the novel coronavirus that causes COVID-19.
Synovis Life Technologies, Inc., today reported its financial results for the third quarter ended July 31, 2010.
BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).
In a new study, Swedish researchers speculate the effects of the present intervention strategies on the healthcare system as the COVID-19 pandemic affects the nation. Their study titled, "Intervention strategies against COVID-19 and their estimated impact on Swedish healthcare capacity," has not been published yet; however, the findings are available as pre-peer-reviewed study at medRxiv.
› Verified 4 days ago
| Entity Name | Catholic Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841623527 PECOS PAC ID: 6103897129 Enrollment ID: O20131207000043 |
News Archive
Scientists have analyzed compounds in wastewater to gauge various aspects of public health, including narcotics usage, antibiotic resistance, and, more recently, the spread of SARS-CoV-2, the novel coronavirus that causes COVID-19.
Synovis Life Technologies, Inc., today reported its financial results for the third quarter ended July 31, 2010.
BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).
In a new study, Swedish researchers speculate the effects of the present intervention strategies on the healthcare system as the COVID-19 pandemic affects the nation. Their study titled, "Intervention strategies against COVID-19 and their estimated impact on Swedish healthcare capacity," has not been published yet; however, the findings are available as pre-peer-reviewed study at medRxiv.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Toufic Imam, MD 160 S River Rd Ste 100, Bedford, NH 03110-6927 Ph: (603) 665-5160 | Toufic Imam, MD 160 S River Rd Ste 100, Bedford, NH 03110-6927 Ph: (603) 665-5160 |
News Archive
Scientists have analyzed compounds in wastewater to gauge various aspects of public health, including narcotics usage, antibiotic resistance, and, more recently, the spread of SARS-CoV-2, the novel coronavirus that causes COVID-19.
Synovis Life Technologies, Inc., today reported its financial results for the third quarter ended July 31, 2010.
BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).
In a new study, Swedish researchers speculate the effects of the present intervention strategies on the healthcare system as the COVID-19 pandemic affects the nation. Their study titled, "Intervention strategies against COVID-19 and their estimated impact on Swedish healthcare capacity," has not been published yet; however, the findings are available as pre-peer-reviewed study at medRxiv.
› Verified 4 days ago
Connie J Campbell, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 9 Washington Pl, Suite 203, Bedford, NH 03110 Phone: 603-656-0326 Fax: 603-656-0329 |